A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis D Infection

Interventions

DRUG: Brelovitug 300 mg
DRUG: Bulevirtide 2 mg and Brelovitug - 300 mg

Sponsor

Mirum Pharmaceuticals, Inc.